Katalyze AI Raises $10.5M Seed
Katalyze AI, based in San Francisco, announced a $10.5 million seed funding round to accelerate the development of its agentic operating system for the pharmaceutical industry. The company currently provides a platform that unifies fragmented production data for biopharma companies, allowing for the deployment of autonomous agents to handle complex engineering, scientific, and manufacturing tasks.
This funding round was led by Bonfire Ventures. Participating investors included Inovia Capital, Ripple Ventures, Alumni Ventures, and angel investors Gokul Rajaram and Farzad Soleimani.
Katalyze AI plans to use the new capital to expand its team across engineering, science, and go-to-market functions. The company also intends to grow its catalog of domain-trained agents and scale deployments with its current base of global pharmaceutical clients.
Founded by Reza Farahani, Shreyas Becker, Hannes Bretschneider, and Matt Cruz, Katalyze AI provides an agentic operating system specifically built for the pharmaceutical sector. The platform integrates with existing lab and plant systems to provide a traceable, GxP-native foundation for AI agents to perform complex workflows in drug development and manufacturing.
Funding Details
Company Website: https://katalyzeai.com
Company: Katalyze AI
Raised: $10.5M
Round: Seed
Funding Date: July 6, 2026
Lead Investor: Bonfire Ventures
Additional Investors: Inovia Capital, Ripple Ventures, Alumni Ventures, Gokul Rajaram, Farzad Soleimani
Company Website: https://katalyzeai.com/
Software Category: Enterprise AI